Glucose‐lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types
Authors' conclusion
Disparities in GLD types and combination therapy were evident between migrants and native Danes. Migrants were more likely to use oral GLDs and less likely to use injection-based GLDs, particularly GLP-1RAs, which may contribute to complication risk and mortality among this group.
Study context
- Population
- Individuals with prevalent T2D on December 31, 2018, Denmark
- Participants
- 253,364 individuals
- Exposure
- Migrants by origin vs native Danes
- Outcome
- User prevalence of GLD combination therapies and individual GLD types
- Follow-up
- 2019
Methodological detailsnationwide, register-based
- Nationwide
- Register-based
Main finding
As reported in the abstract
Combination therapy
Native Danes
34.7%
Each group vs native DanesRelative risk (95% CI)
Migrants (Somalia)lowest of migrant groups
0.78(0.71–0.85)
Migrants (Former Yugoslavia)highest of migrant groups
1.00(0.97–1.04)
Observational data: associations, not effects.
Further findings
| Outcome | Native Danes | Estimate | |
|---|---|---|---|
| Oral GLD use · 2019Migrants (Europe)vs Native DanesLowest of migrant groups · Native Danes value is metformin use | RR, any oral GLD 0.99 (95% CI 0.97–1.01) | ||
| Metformin | 62.1% | ||
| DPP-4i | 13.3% | ||
| SGLT2i | 11.9% | ||
| SU | 5.2% | ||
| Oral GLD use · 2019Migrants (Sri Lanka)vs Native DanesHighest of migrant groups · Native Danes value is metformin use | RR, any oral GLD 1.09 (95% CI 1.06–1.11) | ||
| Insulin use · 2019Migrants (Sri Lanka)vs Native DanesLowest of migrant groups | 18.7% | RR 0.66 (95% CI 0.62–0.71) | |
| Insulin use · 2019Migrants (Europe)vs Native DanesHighest of migrant groups | RR 0.94 (95% CI 0.89–0.99) | ||
| GLP-1 RA use · 2019Migrants (Somalia)vs Native DanesLowest of migrant groups | 13.3% | RR 0.29 (95% CI 0.22–0.39) | |
| GLP-1 RA use · 2019Migrants (Europe)vs Native DanesHighest of migrant groups | RR 0.95 (95% CI 0.89–1.01) | ||
| 0.20.5125Ratio (log scale) |
Oral glucose-lowering drug (GLD) use · 2019
- User prevalence higher in most migrant groups
Insulin use · 2019
- Use less prevalent in migrants
GLP-1 RA use · 2019
- Use less prevalent in migrants
Original publication
Glucose‐lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types. Diabetes Obes Metab. Published 7 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →